Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia

European Journal of Haematology

Volumn 63, Issue 1, 1999, Pages 35-41

  Hellmann, A ^a   Lewandowski, K ^a   Zaucha, J M ^a   Bieniaszewska, M ^a   Halaburda K ^a   Robak, Tadeusz ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

2 Chlorodeoxyadenosine; Efficiency; Side effects; Waldenstrom's macroglobulinemia

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CLADRIBINE; PREDNISONE; PURINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0033017554     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01848.x     Document Type: Article

References (31)

1. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992;340:952-956.
2. Robak T. Cladribine (2-chlorodeoxyadenosine) in the treatment of haematologic malignancies. Appl Biol Commun 1996;6: suppl. 1. 75-90.
3. Carson DA, Wasson DB, Teatle R, You A. Specific toxicity of 2-chlorodeoxyadenosine foward resting and proliferating human lymphocytes. Blood 1983;62:737-743.
4. Kazimierczuk Z, Cottam HB, Ravanliar IR, Robins RK. Synthesis of of 2′-deoxytubericin, of 2′-deoxyadenosin and related 2′-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure. J Am Chem Soc 1984;106:6379-6382.
5. Carrera CJ, Saven A, Piro LD. Purine metabolism of lymphocytes. Hematol Oncol Clin N Am 1994;8:357-381.
6. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117-1121.
7. Juliusson I, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA). Relation to oportunistic infections. Blood 1992;79:888-894.
8. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72:1069-1073.
9. Julliusson G, Liliermark J. High complete remission rate from B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993;11:679-689.
10. Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992;10:371-377.
11. Robak T, Gora-Tybor J, Krykowski E, et al. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-hodgkin's lymphoma. Leuk Lymph 1997;26:99-105.
12. Dimopoulos M, Kantarjan H, Estey E, et al. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993;118:195-198.
13. Dimopoulos A, Kantaruan H, Weber D, et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994;12:2694-2698.
14. Fridrik M, Jager G, Baldinger C, Krieger O, Chott A, Bettelheim P. First-line treatment of Waldenström's disease with cladribine. Ann Hematol 1997;74:7-10.
15. Betticher DC, Hsu Schmitz SE, Ratschiller D, et al. Cladribine (2-CdA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinemia. Br J Haematol 1997;99:358-363.
16. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2-deoxyadenosine in humans. Cancer Res 1991;51:70-72.
17. Saven A, Cheung WK, Smith I, et al. Pharmacokinetic study of oral and bolus intravenous 2-chlroodeoxyadenosine in patients with malignancy. J Clin Oncol 1996;14:978-983.
18. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995;1:385-391.
19. Robak T, Blasińska-Morawiec M, Krykowski E, et al. 2-Chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymph 1996;22:107-111.
20. Rosak T, Błasińska-Morawiec M, Błonski JZ, et al. The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukemia. Eur J Cancer 1997;33:2347-2351.
21. Juliusson G, Liliemark J. Long term survival following cladribinc (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol 1996;7:373-379.
22. Dalannoy A, Ferrant A, Martiat P, Bosly A, Zenebergh A, Michaux JL. 2-Chlorodeoxyadenosine therapy in Waldenström's macroglobulinemia. Nouv Revue Franc d'Hematol 1994;36:317-320.
23. World Health Organisation. Handbook for Reporting Results of Cancer Treatment W.H.O Ofset Publication no 48, Genewa, Switzerland, 1979.
24. Dimopoulos M, Alexanian R. Waldenström's macroglobulinemia. Blood 1994;83:1452-1459.
25. Zinzani PL, Cherlinzoni F, Bendandi M, et al. Fludarabine treatment in resistant Waldenström's macroglobulinemia. Eur J Haematol 1995;62:120-123.
26. Kantarijan HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990;75:1928-1931.
27. Dimopoulos M, Weber K, Delasalle M, Keating M, Alexanian R. Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors. Ann Oncol 1995;6:49-52.
28. Dimopoulos M, Weber K, Delasalle M, Keating M, Alexanian R. Treatment of Waldenström's macro-globulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors. Ann Oncol 1995;6:49-52.
29. Dimopoulos M, O'Brien S, Kantarijan H, Estey E, Keating M, Alexanian R. Treatment of Waldenström's macroglobulinemia with nucleoside analogues. Leuk Lymph 1993;11(suppl.2):105-108.
30. O'Brien S, Kantarijan H, Keating M. Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia. Ann Oncol 1996;7(suppl.6):S27-S33.
31. Robak T, Blasińska-Morawiec M, Krykowski E, et al. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymph 1996;202:509-514.